Eurofins stock faces softer 2026 outlook as Citi lifts target

Eurofins Scientific enters the weekend with a more cautious 2026 growth outlook, while Citi has raised its price target for the laboratory-testing group. The company update and analyst action were reported during the week through Friday, October 30.

Eurofins stock traded at 87.62 euros on Lang & Schwarz at 10:03:35 CET on Saturday, October 31, 2026. Investors can follow the real-time quote of Eurofins stock for the latest trading indication.

Growth improves, guidance softens

Simply Wall St said on Friday, October 30, that Eurofins now expects 2026 organic growth below its previous mid-single-digit objective. The change reflects slower-than-normal market conditions and clinical programs that are not expected to restart in 2026.

The same analysis said acquisition revenue is expected to exceed the previous annualized objective of 250 million euros, supported by completed transactions such as Element's North America Life Sciences Testing Services business. That makes integration execution and the recovery of underlying demand central to the investment case.

Citi raises target, keeps Neutral view

Markets Insider reported on Friday, October 30, that Citi raised its Eurofins price target to 87.50 euros from 73.70 euros and kept a Neutral rating. The move signals a more constructive target level without changing the bank's stated rating.

Eurofins' investor-relations page says the group published its nine-month 2026 trading update on Wednesday, October 21, before the opening of Euronext Paris. The company continues to frame profitability and cash flow as important parts of its medium-term objectives.

French market context remains linked to the CAC 40.

More news and analyses on Eurofins Scientific stock